Systemic availability of 5-aminosalicylic acid: Comparison of delayed release and an azo-bond preparation

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 4, 1996, Pages 601-605

  Gionchetti, P ^a,b   Campieri, M ^a   Venturi, A ^a   Rizzello, F ^a   Ferretti, M ^a   Brignola, C ^a   Miglioli, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; OLSALAZINE;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; DRUG UPTAKE; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; ULCERATIVE COLITIS;

EID: 0030016547     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.26168000.x     Document Type: Article

References (27)

1. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; ii: 892-5.
2. Van Hees PAM, Bakker JH, van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980; 25; 632-5.
3. Klotz U, Maier K, Fischer C, Heinekel K. Therapeuthic efficacy of sulfasalazine and its metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis and Crohn's Disease. N Engl J Med 1980; 303: 1499-502.
4. Goldman P. Will there be a next generation of sulfasalazine? Gastroenterology 1982; 83: 1138-41.
5. Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol 1982; 14: 405-8.
6. Klotz U, Maier KE, Fisher C, Bauer KH. A new slow release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Arzneimittelforschung 1985; 35: 636-9.
7. Rasmussen SN, Bondesen S, Hvidberg EF, et al. 5-aminosalicylic acid in a slow release preparation: bioavailability, plasma levels, and excretion in humans. Gastroenterology 1982; 83: 1062-70.
8. Ryde M, Ahnfelt NO. The pharmacokinetics of olsalazine sodium in healthy volunteers after single iv dose and after oral doses with and without food. Eur J Clin Pharmacol 1988; 34: 481-8.
9. Lauritsen K, Hansen J, Ryde M, et al. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 1984; 86: 1496-500.
10. Dew MJ, Ryder RPI, Evans N, et al. Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis, Br J Clin Pharmacol 1983; 86: 1496-1500.
11. Rijk CMC, van Schaik A, van Tongeren JHM. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivery compounds. Scand J Gastroenterol 1988; 23: 107-12.
12. Christensen LA, Fallinborg J, Abligard K, et al. Topical and systemic availability of 5-aminosalicylate: comparison of three controlled release preparations in man. Aliment Pharmacol Ther 1990; 4: 523-33.
13. Staerk Laursen L, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis; comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990; 31: 1271-6.
14. SAS Institute Inc. SAS STAT User's Guide: Statistics, Volume 2, 4th Edn, Version 6. Cary, NC: SAS Institute Inc. 1989: 846.
15. Lauritsen K, Laursen LS, Bukshave K, et al. Long term olsalazine treatment: pharmacokinetics, tolerance and effect on local eicosanoid formation in ulcerative colitis and Crohn's colitis. Gut 1988; 29: 974-82.
16. Dew MJ, Ryder REJ, Evans N, et al. J. Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis. Br. J Clin Pharmacol 1983; 16: 185-7.
17. Christensen LA, Fallinborg J, Jacobsen BA, et al. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Aliment Pharmacol Ther 1994; 8: 289-94.
18. Jarnerot G. Clinical tolerance of olsalazine. Scand J Gastroenterol 1988; 23 (Suppl. 148): 21-3.
19. Dew MJ, Hughes P, Harries AD, et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J 1982; 285: 1012.
20. R) and sulphasalazine for maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1989; 3: 183-91.
21. Mulder CJJ, Tytgat GNJ, Weterman IT, et al. Double-blind comparison of slow-release 5-aminosalicylate and sulphasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1989; 95: 1449-53.
22. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 1988; 29: 835-7.
23. Calder IC, Williams PJ, Woods RA et al. Nephrotoxicity and molecular structure. Xenobiotica 1975; 5: 303-7.
24. Calder IC, Funder CC, Green CR, Ham KN, Tangew JD, Neprotoxicity lesions from 5-aminosalicylic acid. Br Med J 1972; i: 152-4.
25. Novis BJJ, Korzets Z, Chen P, et al. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J 1988; 296: 1442.
26. von Muhlendahl KE. Nephritis during 5-aminosalicylic acid. Dtsch Med Wochenschr 1989; 114: 236.
27. Thuluvath PJ, Ninkovic M, Calam J, et al. Mesalazine induced interstitial nephritis. Gut 1994; 35: 1493-6.